Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.

NCT03673826 is registered in ClinicalTrials.gov with Stichting Hemato-Oncologie voor Volwassenen Nederland as lead sponsor.

NCT NCT03673826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03673826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.
Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 19, 2018
Completion date
December 31, 2028
Enrollment
58 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

smouldering myeloma